8.69 USD
-0.31 (-3.44%)
At close: Jan 30, 2026
8.6 USD
-0.09 (-1.04%)
After Hours: 1/30/2026, 8:00:02 PM
INBS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 184 industry peers in the Health Care Equipment & Supplies industry. Both the profitability and financial health of INBS have multiple concerns. INBS has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
- INBS had negative earnings in the past year.
- In the past year INBS has reported a negative cash flow from operations.
- In the past 5 years INBS always reported negative net income.
- In the past 5 years INBS always reported negative operating cash flow.
1.2 Ratios
- With a Return On Assets value of -108.25%, INBS is not doing good in the industry: 80.98% of the companies in the same industry are doing better.
- INBS has a Return On Equity of -300.07%. This is in the lower half of the industry: INBS underperforms 77.17% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -108.25% | ||
| ROE | -300.07% | ||
| ROIC | N/A |
ROA(3y)-101.5%
ROA(5y)-80.79%
ROE(3y)-251.51%
ROE(5y)-185.33%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- Looking at the Gross Margin, with a value of 43.09%, INBS is doing worse than 65.76% of the companies in the same industry.
- The Profit Margin and Operating Margin are not available for INBS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 43.09% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for INBS has been increased compared to 1 year ago.
- INBS has more shares outstanding than it did 5 years ago.
- INBS has a better debt/assets ratio than last year.
2.2 Solvency
- INBS has an Altman-Z score of -4.36. This is a bad value and indicates that INBS is not financially healthy and even has some risk of bankruptcy.
- INBS has a Altman-Z score of -4.36. This is in the lower half of the industry: INBS underperforms 69.57% of its industry peers.
- A Debt/Equity ratio of 0.04 indicates that INBS is not too dependend on debt financing.
- The Debt to Equity ratio of INBS (0.04) is better than 68.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.04 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.36 |
ROIC/WACCN/A
WACC10.08%
2.3 Liquidity
- INBS has a Current Ratio of 0.89. This is a bad value and indicates that INBS is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Current ratio of INBS (0.89) is worse than 87.50% of its industry peers.
- A Quick Ratio of 0.76 indicates that INBS may have some problems paying its short term obligations.
- Looking at the Quick ratio, with a value of 0.76, INBS is doing worse than 83.70% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.76 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 54.16% over the past year.
- INBS shows a small growth in Revenue. In the last year, the Revenue has grown by 3.27%.
- The Revenue has been growing by 74.49% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)54.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-395.27%
Revenue 1Y (TTM)3.27%
Revenue growth 3Y91.13%
Revenue growth 5Y74.49%
Sales Q2Q%27.5%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y128%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year126.26%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for INBS. In the last year negative earnings were reported.
- INBS is valuated rather expensively with a Price/Forward Earnings ratio of 24.34.
- Based on the Price/Forward Earnings ratio, INBS is valued a bit cheaper than the industry average as 76.09% of the companies are valued more expensively.
- INBS is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 25.57, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 24.34 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
- INBS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
INTELLIGENT BIO SOLUTIONS IN / INBS FAQ
Can you provide the ChartMill fundamental rating for INTELLIGENT BIO SOLUTIONS IN?
ChartMill assigns a fundamental rating of 1 / 10 to INBS.
What is the valuation status of INTELLIGENT BIO SOLUTIONS IN (INBS) stock?
ChartMill assigns a valuation rating of 2 / 10 to INTELLIGENT BIO SOLUTIONS IN (INBS). This can be considered as Overvalued.
How profitable is INTELLIGENT BIO SOLUTIONS IN (INBS) stock?
INTELLIGENT BIO SOLUTIONS IN (INBS) has a profitability rating of 0 / 10.
What is the earnings growth outlook for INTELLIGENT BIO SOLUTIONS IN?
The Earnings per Share (EPS) of INTELLIGENT BIO SOLUTIONS IN (INBS) is expected to grow by 128% in the next year.